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Antenatal Bartter syndrome (ABS) is a rare autosomal recessive renal tubular disorder. The defective chloride transport in
the loop of Henle leads to fetal polyuria resulting in severe hydramnios and premature delivery. Early onset, unexplained
maternalpolyhydramniosoftenchallengesthetreatingobstetrician.Increasingpolyhydramnioswithoutapparentfetalorplacental
abnormalities should lead to the suspicion of this entity. Biochemical analysis of amniotic ﬂuid is suggested as elevated
chloride level is usually diagnostic. Awareness, early recognition, maternal treatment with indomethacin, and amniocentesis
allow the pregnancy to continue. Aﬀected neonates are usually born premature, have postnatal polyuria, vomiting, failure to
thrive, hypercalciuria, and subsequently nephrocalcinosis. Hypokalemia, metabolic alkalosis, secondary hyperaldosteronism and
hyperreninaemia are other characteristic features. Volume depletion due to excessive salt and water loss on long term stimulates
renin-angiotensin-aldosteronesystemresultinginjuxtaglomerularhyperplasia.Clinicalfeaturesandelectrolyteabnormalitiesmay
also depend on the subtype of the syndrome. Prenatal diagnosis and timely indomethacin administration prevent electrolyte
imbalance, restitute normal growth, and improve activity. In this paper, authors present classiﬁcation, pathophysiology, clinical
manifestations, laboratory ﬁndings, complications, and prognosis of ABS.
1.Introduction
Bartter syndrome is a rare renal tubulopathy ﬁrst described
by Frederic Bartter in 1962. The primary pathogenic mech-
anism is defective transepithelial chloride reabsorption in
thick ascending limb of loop of Henle (TALH). The disease
is characterized by hypokalemia, metabolic alkalosis, and
secondary hyperaldosteronism with normal to low blood
pressure due to renal loss of sodium and hyperplasia of
juxtaglomerular apparatus [1, 2]. There are two distinct
presentations of Bartter syndrome, namely; antenatal Bartter
syndrome (ABS) and classical Bartter syndrome. ABS is
the severe form having onset in utero. The awareness
of the condition is important for early recognition. The
typical features include fetal polyuria, early onset maternal
polyhydramnios, intrauterine growth restriction, preterm
birth, postnatal polyuria, episodes of dehydration, recurrent
vomiting, and failure to thrive [3, 4]. Another syndrome,
Gitelman syndrome, is often called as variant of Bartter
syndrome. This is a rare autosomal recessive disorder
characterized by late onset hypokalemic metabolic alkalosis,
hypocalciuria, and hypomagnesemia. History of maternal
hydramnios or prematurity will be absent. They are fre-
quently asymptomatic. Muscular weakness and tetany may
be present sometimes. Polyuria and growth retardation are
not major manifestations. Plasma renin and aldosterone are
increased but not to the degree seen in Bartter syndrome.
Urinary prostaglandins are not increased.
2. Classiﬁcationand Inheritanceof
BartterSyndrome
Antenatal Bartter syndrome has four variants [5, 6]w i t h
mild diﬀerences in phenotype and genotype (Table 1).
Principal clinical features in most of them include early
onset polyhydramnios, failure to thrive, prematurity, and
nephrocalcinosis. Types I, II, and III have severe antenatal
symptoms, prematurity, and failure to thrive, while type
IV is a mild salt losing nephropathy with mild antenatal2 International Journal of Pediatrics
Table 1: Pharmacological classiﬁcation of Bartter syndrome with important clinical features.
Subtypes Gene loci Molecule aﬀected Molecule implicated Site in renal
tubule
Pharmacological
classiﬁcation Important clinical features
Antenatal
Bartter
syndrome
I (601678) SLC12A1/15q21.1 Na-K-2Cl
cotransporter TAL Pure frusemide type
Severe maternal
polyhydramnios,
hypercalciuria,
nephrocalcinosis
Antenatal
Bartter
syndrome
II (241200) KCNJ1/11q24 Kir1.1 potassium
channel TAL Thiazide type
Hypochloremia,
hypomagnesemia, failure to
thrive in infancy, EAST
syndrome
Classic Bartter III (602522) CLCNKB/1p36 ClC-Kb chloride
channel DCT Thiazide type
Hypomagnesemia,
hypocalciuria, EAST
syndrome
Bartter
syndrome with
senosorineural
deafness
IV (606412)
BSND/1p31 or
CLCNKA-
CLCNKB/1p36
Barttin, ClC-Ka and
ClC-Kb chloride
channels
TAL+DCT Thiazide-frusemide
type
Polyuria, hypochloremia, mild
hypomagnesemia, SND, CRF
TAL: thick ascending loop of Henle, TAL: thin ascending loop of Henle, DCT: distal cortical tubule, EAST syndrome: epilepsy, ataxia, sensorineural deafness,
tubulopathy, SND: sensorineural deafness, and CRF: chronic renal failure.
symptoms. Type IV involves chloride channels which are
present in distal nephron as well as in inner ear resulting in
sensorineural hearing lossinaddition. Table 1 showsthenew
pharmacology based classiﬁcation with details of the types
and molecules aﬀected in each of them. This classiﬁcation
is designed on Bartter syndrome for easy understanding as
students and young physicians are more familiar with phar-
macologic actions of diuretics at each level of nephron [6].
3.Pathophysiology
Thick ascending loop of Henle (TAL) has channels, namely,
Na-K-2Cl cotransporter, K+ (ROMK: rat outer medulla
potassium), and chloride (CIC-Kb) channels which are
responsibleforelectrolyteabsorption. Eachofthesechannels
is coded by a speciﬁc gene (Table 1). Any mutation in
gene results in impaired channel function and hence defec-
tive electrolyte reabsorption. K+ transport occurs through
ROMK channel, whereas Na+ and Cl− get absorbed from
the luminal space. Passage of Cl− from the cell into the
interstitium can take place through kidney-speciﬁc chloride
channels (CIC-Kb) and via K+/Cl− cotransport system. In
the apical membrane, there is also an exchange of Na+/H+.
Thus, the handling of chloride ions by the thick ascending
loopofHenle(TALH)isanintimatepartofthenormalfunc-
tion of Na+ K+ 2CI− electroneutral cotransport, as well as
K+ channels (ROMK) and Cl− channels (CIC-Kb). Any loss
o ra l t e r e df u n ct i o no fN a +-K+-2CI− cotransporter and/or K+
channels as well as chloride channels results in defective Cl−
transport. This defect will result in malreabsorption of Na+,
K+,C l −,a n dC a 2+ in the TALH and delivery of large volumes
of urine with a high content of Na+,K +,C l −,a n dC a 2+ to the
distal tubule. In the distal tubule, part of the delivered Na+
will be reabsorbed in exchange for intracellular K+.H e n c e ,
potassium wasting occurs. Impaired Na absorption in TALH
will result in increased levels of prostaglandin E2. Increased
PGE2 will exacerbate primary defect of chloride transport
in TALH which will stimulate renin angiotensin-aldosterone
axis causing hypokalemia (due to hyperaldosteronism),
and impede water reabsorption in collecting ducts leading
to hyposthenuria (Figures 1 and 2). Hyperaldosteronism
increases K wasting and stimulates exchange of intracellular
H ions for K ions for intraluminal K (distal tubule and
collecting duct) resulting in exaggeration of metabolic
alkalosis. The normal blood pressure despite high levels of
renin and angiotensin is thought to be due to nonresponsive
of their blood vessels to angiotensins [1–7]. Continuous loss
of calcium in urine results in nephrocalcinosis [2–4].
4.ClinicalFeatures
Mothers of fetus with Bartter syndrome often present with
unexplained polyhydramnios between 24 and 30 weeks of
gestation [3, 4, 7]. Intrauterine growth restriction may also
be associated. Inability of the kidney tubule to retain salt
and water results in fetal polyuria. Important biochemi-
cal abnormality in amniotic ﬂuid is normal sodium and
potassium but consistently elevated chloride levels [4, 8–
12]. Infants are usually born preterm. After birth, important
diagnostic ﬁnding is hyposthenuria and rapid weight loss.
Poor feeding and lethargy are the other symptoms. Urine
examination shows low speciﬁc gravity, normal potassium
but high sodium and chloride levels. However, after 1–3
weeks, level of potassium considerably rises above normal
with relatively less sodium than in the ﬁrst week of life.
Prostaglandin levels are high in blood and urine as a
secondary phenomenon [5, 6, 9, 13]. Impaired sodium
absorption in TALH will result in increased levels of
prostaglandin E2 [13, 14]. If the diagnosis gets delayed,
infants may present with poor feeding, dehydration, and
severe electrolyte imbalance. Transient hyperkalemia may be
observed in type II ABS. Blood pressure is usually normal.
Growth faltering, dwarﬁsm, polydipsia, and weakness may
be present in older children. Mild mental retardation isInternational Journal of Pediatrics 3
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Figure 1: Pathophysiology of Bartter syndrome.
reported in few patients. Facial features such as triangular
face, prominent forehead, large eyes, protruding ears, and
drooping mouth may be present [15, 16]. Sensorineural
deafness is seen in type IV Bartter syndrome. Strabismus,
convulsions, and increased susceptibility to infections are
also reported [15, 16]. Urinary electrolytes except potassium
in second trimester are low in mother’s urine in cases of
Bartter syndrome [17].
5. LaboratoryInvestigations
When there is early onset unexplained maternal polyhy-
dramnios, ultrasonography should be performed to conﬁrm
structurally normal fetus and placenta. If ABS is strongly
suspected, one should do amniocentesis and subject amni-
otic ﬂuid for biochemical analysis. High chloride in amniotic
ﬂuid is a consistent ﬁnding and diagnostic of ABS [4, 9, 17].
Other electrolytes in the amniotic ﬂuid will be normal. In
aﬀected neonates, serum and urinary electrolyte estimation
is important. Urinary electrolytes show increased sodium,
potassium, and chloride levels. Hypokalemia is the usually
observed serum electrolyte abnormality. Blood gas analysis
detectsmetabolicalkalosis.Plasmareninwillbeusuallyhigh.
Ultrasonography of the kidneys detects bilateral medullary
nephrocalcinosis which is observed after several weeks of
severe hypercalciuria [2, 4, 11]. Mutational analysis of the
genomic DNA will identify the fundamental defect [5].
6. Complications
The important complications of ABS include hypercalciuria
leading to nephrocalcinosis [2, 4, 11, 12]a n dg r o w t h
restriction. Sensorineural deafness is associated with Bartter
syndrome IV. Defects in the barttin subunit of the ClC-Ka
and CIC-Kb channels are responsible for sensorineural deaf-
ness [15]. Very rarely progressive renal disease, renal failure,
and interstitial nephritis can occur. Acute renal failure from
rhabdomyolysis due to hypokalemia has also been reported.
7. Treatment
Prenatal diagnosis can be made by the high chloride
content of the amniotic ﬂuid [18–20] and mutational anal-
ysis of genomic DNA extracted from cultured amniocytes
obtained by amniocentesis [21]. Once ABS is conﬁrmed,
mother should be treated antenatally at the earliest with
indomethacin (1mg/kg/day) in two divided doses [22].
Indomethacin inhibits prostaglandin synthetase, decreases
renal salt wasting, reduces fetal urine output, and thereby
controls polyhydramnios. Indomethacin may lead to con-
striction of ductus arteriosus. Hence, patency of ductus
arteriosus needs to be monitored in all such fetuses. Rapidly
increasing hydramnios may require therapeutic amniocen-
tesis. Indomethacin therapy and therapeutic amniocentesis
usually allow the pregnancy to continue. Following birth,4 International Journal of Pediatrics
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Figure 2: Pictorial representation of ion transporters in thick ascending limb of Loop of Henle (TAL) and distal convoluted tubule (DCT).
neonate should be monitored for urine output, hydra-
tion, weight loss, and electrolyte balance. Correction of
dehydration and electrolyte imbalance are the important
aspects of management. Potassium supplements are usually
needed by 2-3 weeks. Prostaglandin synthetase inhibitors
are usually required for the disease control. Indomethacin
at a dose of 1–5mg/kg is usually recommended and well
tolerated [18, 22, 23]. Early initiation of indomethacin
may be required in neonatal Bartter syndrome caused by
mutations atgene coding forthe NKCC2 transporter. Beneﬁt
from initiation of indomethacin therapy at 4–6 weeks and
doses below 1mg/kg/day is likely in patients with mutations
at the ROMK channel gene [19]. Indomethacin has side-
eﬀects on gastrointestinal tract. Colonic perforation after
indomethacin administration has been reported emphasiz-
ing the importance of careful monitoring [24]. Other drugs
used are acetylsalicylic acid (100mg/kg/day), ibuprofen
(30mg/kg/day), or ketoprofen (20mg/kg/day). Addition of
potassium sparing diuretics may be initially eﬀective in the
control of hypokalemia, but their eﬀect is transient. Caution
in such treatment is required as treatment with potassium
sparing diuretics may be dangerous in situations of gross
salt and water wasting and circulatory volume contraction.
Long-term prognosis is guarded. Lack of satisfactory control
mayleadtomorbidity,growthfailure,andrenalinsuﬃciency
[2, 18, 23].
8.Prognosis
Untreated ABS patients may succumb to dehydration,
dyselectrolytemia, and intercurrent infections. Timely and
appropriate therapy results in clinical improvement and
catch up growth in majority of children. Long-term outcome
includingmentaldevelopmentandpubertyisusuallynormal
[2, 18, 23]. Growth retardation is a uniform feature in nearly
all patients with Bartter syndrome. Developmental delay
has also been described in earlier reports. Hypokalemia,
hypercalciuria, and nephrocalcinosis may lead to chronic
tubulointerstitial nephropathy and progressive reduction in
GFR. Renal failure is likely to occur especially in children
with BSND mutations. Renal failure requiring dialysis or
transplantation is fairly uncommon in Bartter syndrome.
Brochard et al. [25] reported chronic renal failure in 3 out of
42 children with a median followup of 8.3 years. Satisfactory
prognosis after a median followup of more than 10 years and
gallstones representing a new complication of ABS has also
been reported [26]. Beneﬁts from renal transplantation have
been mentioned. Spontaneous recovery of ABS following a
period of treatment has been recognized [27].
References
[ 1 ]F .C .B a r t t e r ,P .P r o n o v e ,J .R .G i l lJ r . ,a n dR .C .M a c C a r d l e ,
“Hyperplasia of the juxtaglomerular complex with hyperal-
dosteronism and hypokalemic alkalosis. A new syndrome,”
American Journal of Medicine, vol. 33, pp. 811–828, 1962.
[2] K. M. Dell and E. D. Avner, “Bartter-Gitelman syndromes and
other inherited tubular transport abnormalities,” in Nelson
Textbook of Pediatrics, R. M. Kleigman, R. E. Behrman, H.
B. Jenson, and B. F. Stanton, Eds., pp. 2201–2202, Saunders,
Philadelphia, Pa, USA, 18th edition, 2007.
[3] W. Proesmans, “Bartter syndrome and its neonatal variant,”
European Journal of Pediatrics, vol. 156, no. 9, pp. 669–679,
1997.
[4] Y. R. Bhat, G. Vinayaka, R. Vani, K. A. Prashanth, and K.
Sreelakshmi, “Antenatal Bartter syndrome: a rare cause of
unexplainedseverepolyhydramnios,”AnnalsofTropicalPaedi-
atrics, vol. 31, pp. 153–157, 2011.
[5] K. Brochard, O. Boyer, A. Blanchard et al., “Phenotype-geno-
type correlation in antenatal and neonatal variants of BartterInternational Journal of Pediatrics 5
syndrome,” Nephrology Dialysis Transplantation,v o l .2 4 ,n o .5 ,
pp. 1455–1464, 2009.
[6] H. W. Seyberth and K. P. Schlingmann, “Bartter and Gitel-
man-like syndromes: salt-losing tubulopathies with loop or
DCT defects,” Pediatric Nephrology, vol. 26, pp. 1789–1802,
2011.
[7] P.R.RodrıguezandT.Hasaart,“Hydramniosandobservations
in Bartter’s syndrome,” Acta Obstetricia et Gynecologica Scan-
dinavica, vol. 61, pp. 477–478, 1982.
[ 8 ]G .M a s s a ,W .P r o e s m a n s ,H .D e v l i e g e r ,K .V a n d e n b e r g h e ,A .
van Assche, and E. Eggermont, “Electrolyte composition of
the amniotic ﬂuid in Bartter syndrome,” European Journal of
Obstetrics & Gynecology and Reproductive Biology, vol. 24, pp.
335–340, 1987.
[9] B. Dane, M. Yayla, C. Dane, and A. Cetin, “Prenatal diagnosis
of Bartter syndrome with biochemical examination of amni-
otic ﬂuid: case report,” Fetal Diagnosis and Therapy, vol. 22,
no. 3, pp. 206–208, 2007.
[10] J. Rodr´ ıguez-Soriano, “Bartter and related syndromes: the
puzzle is almost solved,” Pediatric Nephrology, vol. 12, no. 4,
pp. 315–327, 1998.
[11] A. Ohlsson, U. Sieck, W. Cumming, M. Akhtar, and F. Sereni-
us, “A variant of Bartter’s syndrome. Bartter’s syndrome
associated with hydramnios, prematurity, hypercalciuria and
nephrocalcinosis,” Acta Paediatrica Scandinavica, vol. 73, no.
6, pp. 868–874, 1984.
[12] W. Proesmans, H. Devlieger, and A. Van Assche, “Bartter syn-
drome in two siblings - Antenatal and neonatal observations,”
International Journal of Pediatric Nephrology, vol. 6, no. 1, pp.
63–70, 1985.
[13] M. J. Dunn, “Prostaglandins and Bartter’s syndrome,” Kidney
International, vol. 19, no. 1, pp. 86–102, 1981.
[14] M. H. Winterborn, G. J. Hewitt, and M. D. Mitchell, “The role
of prostaglandins in Bartter’ssyndrome,” InternationalJournal
of Pediatric Nephrology, vol. 5, no. 1, pp. 31–38, 1984.
[15] D. Landau, H. Shalev, M. Ohaly, and R. Carmi, “Infantile
variant of Bartter syndrome and sensorineural deafness: a new
autosomal recessive disorder,” American Journal of Medical
Genetics, vol. 59, no. 4, pp. 454–459, 1995.
[16] G. Madrigal, P. Saborio, F. Mora, G. Rincon, and L. M. Guay-
Woodford, “Bartter syndrome in Costa Rica: a description of
20 cases,” Pediatric Nephrology, vol. 11, no. 3, pp. 296–301,
1997.
[17] Y. Matsushita, Y. Suzuki, N. Oya et al., “Biochemical exam-
ination of mother’s urine is useful for prenatal diagnosis of
Bartter syndrome,” Prenatal Diagnosis, vol. 19, no. 7, pp. 671–
673, 1999.
[18] J. Rodriguez-Soriano, “Tubular disorders of electrolyte regu-
lation,” in Pediatric Nephrology,E .A v n e r ,W .H a r m o n ,a n dP .
Niaudet, Eds., pp. 729–756, Lippincott Williams and Wilkins,
Philadelphia, Pa, USA, 5th edition, 2004.
[19] J. Rodriguez-Soriano, “Bartter’s syndrome comes of age,”
Pediatrics, vol. 103, no. 3, pp. 663–664, 1999.
[20] B. Dane, C. Dane, F. Aksoy, A. Cetin, and M. Yayla, “Antenatal
bartter syndrome: analysis of two cases with placental ﬁnd-
ings,” Fetal and Pediatric Pathology, vol. 29, no. 3, pp. 121–126,
2010.
[ 2 1 ]M .E .N o r t o n ,J .M e r r i l l ,B .A .B .C o o p e r ,J .A .K u l l e r ,a n dR .
I. Clyman, “Neonatal complications after the administration
of indomethacin for preterm labor,” New England Journal of
Medicine, vol. 329, no. 22, pp. 1602–1607, 1993.
[22] M. Konrad, A. Leonhardt, P. Hensen, W. H. Seyberth, and A.
Kockerling, “Prenatal and postnatal management of Hyper-
prostaglandinEsyndromeaftergeneticdiagnosisfromamnio-
cytes,” Pediatrics, vol. 103, pp. 678–683, 1999.
[23] I.AmirlakandK.P.Dawson,“Barttersyndrome:anoverview,”
QJM, vol. 93, no. 4, pp. 207–215, 2000.
[24] E. Ataoglu, M. Civilibal, A. A. Ozkul, I. G. Varal, E. R. Oktay,
and E. Murat, “Indomethacin-induced colon perforation in
Bartter’s syndrome,” Indian Journal of Pediatrics, vol. 76, no.
3, pp. 322–323, 2009.
[25] K. Brochard, O. Boyer, A. Blanchard et al., “Phenotype-geno-
type correlation in antenatal and neonatal variants of Bartter
syndrome,” Nephrology Dialysis Transplantation, vol. 24, no. 5,
pp. 1455–1464, 2009.
[26] E.Puricelli,A.Bettinelli,N.Borsaetal.,“Long-termfollow-up
of patients with Bartter syndrome type i and II,” Nephrology
Dialysis Transplantation, vol. 25, no. 9, pp. 2976–2981, 2010.
[27] S. Reinalter, H. Devlieger, and W. Proesmans, “Neonatal Bart-
ter syndrome: spontaneous resolution of all signs and symp-
toms,” Pediatric Nephrology, vol. 12, no. 3, pp. 186–188, 1998.